Hsu, Chiun

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 4,280

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial

Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,273

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 1,169

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 746

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., et al. (2024) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 101

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 90

An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma

Shen, Y.-C., Lee, P.-C., Kuo, Y.-L., Wu, W.-K., Chen, C.-C., Lei, C.-H., Yeh, C.-P., Hsu, C., Hsu, C.-H., Lin, Z.-Z., et al. (2021) · Journal of Hepatocellular Carcinoma

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 36

Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy

Chen, B.-B., Hsu, C.-Y., Yu, C.-W., Liang, P.-C., Hsu, C., Hsu, C.-H., Cheng, A.-L., & Ting-Fang Shih, T. (2017) · Radiology

Hepatocellular Carcinoma Treatment and PrognosisMRI in cancer diagnosis

Cited by 7

Integrating generative AI Into clinical reasoning education for medical students: Mixed methods study

Liu, C.-H., Chen, Y.-T., Hsu, C., Chen, H.-L., & Yang, C.-W. (2026) · JMIR Medical Education

Artificial Intelligence in Healthcare and EducationClinical Reasoning and Diagnostic Skills

Cited by 3